

Change in number of shares and votes in SynAct Pharma AB

SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 2,521,451 as a result of the preferential share issue, including the payment in shares to the guarantors, resolved upon by the extraordinary general meeting on 13 December 2024.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 49,008,918.

For further information, please contact:

Jeppe Øvlesen, CEO SynAct Pharma

Tel: +45 2844 7567

Email: JOO@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-01-31 18:00 CET.

Attachments

[Change in number of shares and votes in SynAct Pharma AB](#)